Literature DB >> 11279046

Inhibition of interactions and interconversions of prion protein isoforms by peptide fragments from the C-terminal folded domain.

M Horiuchi1, G S Baron, L W Xiong, B Caughey.   

Abstract

The formation of protease-resistant prion protein (PrP-res or PrP(Sc)) involves selective interactions between PrP-res and its normal protease-sensitive counterpart, PrP-sen or PrP(C). Previous studies have shown that synthetic peptide fragments of the PrP sequence corresponding to residues 119-136 of hamster PrP (Ha119-136) can selectively block PrP-res formation in cell-free systems and scrapie-infected tissue culture cells. Here we show that two other peptides corresponding to residues 166-179 (Ha166-179) and 200-223 (Ha200-223) also potently inhibit the PrP-res induced cell-free conversion of PrP-sen to the protease-resistant state. In contrast, Ha121-141, Ha180-199, and Ha218-232 were much less effective as inhibitors. Mechanistic analyses indicated that Ha166-179, Ha200-223, and peptides containing residues 119-136 inhibit primarily by binding to PrP-sen and blocking its binding to PrP-res. Circular dichroism analyses indicated that Ha117-141 and Ha200-223, but not non-inhibitory peptides, readily formed high beta-sheet structures when placed under the conditions of the conversion reaction. We conclude that these inhibitory peptides may mimic contact surfaces between PrP-res and PrP-sen and thereby serve as models of potential therapeutic agents for transmissible spongiform encephalopathies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11279046     DOI: 10.1074/jbc.M100288200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  From conversion to aggregation: protofibril formation of the prion protein.

Authors:  Mari L DeMarco; Valerie Daggett
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

2.  An aggregation-specific enzyme-linked immunosorbent assay: detection of conformational differences between recombinant PrP protein dimers and PrP(Sc) aggregates.

Authors:  Tao Pan; Binggong Chang; Poki Wong; Chaoyang Li; Ruliang Li; Shin-Chung Kang; John D Robinson; Andrew R Thompsett; Po Tein; Shaoman Yin; Geoff Barnard; Ian McConnell; David R Brown; Thomas Wisniewski; Man-Sun Sy
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

3.  PrP Knockout Cells Expressing Transmembrane PrP Resist Prion Infection.

Authors:  Karen E Marshall; Andrew Hughson; Sarah Vascellari; Suzette A Priola; Akikazu Sakudo; Takashi Onodera; Gerald S Baron
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

4.  Isolation and characterization of a polymerized prion protein.

Authors:  Bao-Yuan Lu; Jui-Yoa Chang
Journal:  Biochem J       Date:  2002-05-15       Impact factor: 3.857

Review 5.  Molecular aspects of disease pathogenesis in the transmissible spongiform encephalopathies.

Authors:  Suzette A Priola; Ina Vorberg
Journal:  Mol Biotechnol       Date:  2006-05       Impact factor: 2.695

6.  Nonpathogenic Heterologous Prions Can Interfere with Prion Infection in a Strain-Dependent Manner.

Authors:  Alba Marín-Moreno; Patricia Aguilar-Calvo; José Luis Pitarch; Juan Carlos Espinosa; Juan María Torres
Journal:  J Virol       Date:  2018-11-27       Impact factor: 5.103

Review 7.  Aptamers against prion proteins and prions.

Authors:  Sabine Gilch; Hermann M Schätzl
Journal:  Cell Mol Life Sci       Date:  2009-04-25       Impact factor: 9.261

8.  Characterization of cell-surface prion protein relative to its recombinant analogue: insights from molecular dynamics simulations of diglycosylated, membrane-bound human prion protein.

Authors:  Mari L DeMarco; Valerie Daggett
Journal:  J Neurochem       Date:  2009-02-23       Impact factor: 5.372

Review 9.  Recent advances in prion chemotherapeutics.

Authors:  Valerie L Sim; Byron Caughey
Journal:  Infect Disord Drug Targets       Date:  2009-02

10.  Prion protein self-peptides modulate prion interactions and conversion.

Authors:  Alan Rigter; Jan Priem; Drophatie Timmers-Parohi; Jan P M Langeveld; Fred G van Zijderveld; Alex Bossers
Journal:  BMC Biochem       Date:  2009-11-30       Impact factor: 4.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.